Wall Street closed lower on Tuesday, pulled down by health care, tech and discretionary stocks. Investor mood was grim on the White House’s continued see-sawing on global trade deals, and economic data showing a historic trade deficit. Investors also awaited the Fed’s policy decision. All three benchmark indexes closed the session in the red. How Did the Benchmarks Perform? The Dow Jones Industrial Average (DJI) slid 1%, or 389.83 points, to close at 40,829.00. Twenty-two components of the 30-stock index ended in negative territory, while eight ended in positive. The tech-heavy Nasdaq Composite fell 154.58 points, or 0.9%, to close at 17,689.66. The S&P 500 fell 43.47 points, or 0.8%, to close at 5,606.91. Nine of the 11 broad sectors of the benchmark index closed in the red. The Health Care Select Sector SPDR (XLV), the Industrials Select Sector SPDR (XLI) and the Consumer Discretionary Select Sector SPDR (XLY) declined 2.8%, 0.9% and 0.9%, respectively, while the Utilities Select Sector SPDR (XLU) advanced 1.2%. The fear-gauge CBOE Volatility Index (VIX) increased 4.7% to 24.76. A total of 14.77 billion shares were traded on Tuesday, lower than the last 20-session average of 18.9 billion. Investor Mood Grim on Trump Pushing Back Hopes of Trade Deals Over the past few weeks, Wall Street has recovered from the losses arising from Donald Trump's early-April announcement of plans to impose hefty tariffs on leading trading partners, primarily targeted at China. Investors have remained optimistic that the Trump administration will negotiate trade deals soon to end this tariff war. However, during his meeting with Canadian Prime Minister Mark Carney on Tuesday afternoon, Trump retracted from the promises that trade deals were on the horizon, saying, “We don’t have to sign deals.” Earlier this week, Treasury Secretary Scott Bessent said, “We’re very close to some deals,” following up on Trump’s Sunday comments that agreements could come as early as this week. What the President said on Tuesday is in direct contradiction to the earlier ones, and the markets felt the jitters. Health Care Tumbles on an FDA Appointment The health care sector came under pressure on Tuesday on reports that the Food and Drug Administration had named Dr. Vinay Prasad, a vocal critic of the Covid-19 response, as its top vaccine official. Consequently, shares of Moderna, Inc. MRNA and Merck & Co., Inc. MRK lost 12.3% and 4.6%, respectively. Both currently carry a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Story Continues Oil Prices Recover From 4-Year Low On Tuesday, oil prices rose 3% on expectations of higher demand in Europe and China, lower production in the U.S. and tensions in the Middle East. In the previous session, prices had fallen to a four-year low. Brent crude rose $1.92, or 3.2%, to close at $62.15/barrel, WTI crude added $1.96, or 3.4%, to close at $59.09/barrel. Economic Data Per a government report, the trade deficit for March came in at a historic high for the month, $140.5 billion. This is much higher than $137.5 predicted for the period. The number for February was revised up to a deficit of $123.2 billion from the previously reported $122.7 billion. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Merck & Co., Inc. (MRK):Free Stock Analysis Report Moderna, Inc. (MRNA):Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments
Stock Market News for May 7, 2025
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...